Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

NCT02779569 ·Status: UNKNOWN ·Phase: NA

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

NCT00282399 ·Status: TERMINATED ·Phase: PHASE1

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

NCT00260065 ·Status: COMPLETED ·Phase: PHASE2

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

NCT01026376 ·Status: NO_LONGER_AVAILABLE

A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

NCT01041846 ·Status: COMPLETED

Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome

NCT01409070 ·Status: COMPLETED

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT00619099 ·Status: COMPLETED ·Phase: PHASE2

Decitabine in Treating Patients With Myelodysplastic Syndrome

NCT00003361 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

NCT01497145 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.

NCT02663752 ·Status: TERMINATED ·Phase: PHASE2

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225 ·Status: TERMINATED ·Phase: PHASE2

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

NCT00941109 ·Status: COMPLETED ·Phase: PHASE1

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

NCT00113321 ·Status: TERMINATED ·Phase: PHASE2

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

NCT00067808 ·Status: COMPLETED ·Phase: PHASE2

Decitabine in Treating Patients With Myelofibrosis

NCT00095784 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

NCT02706899 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

NCT00796003 ·Status: COMPLETED ·Phase: PHASE1

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

NCT05636514 ·Status: RECRUITING ·Phase: PHASE1

Efficacy of Decitabine in Clearance of MRD

NCT03021395 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT01687400 ·Status: COMPLETED ·Phase: PHASE2

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

NCT01165996 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

NCT00903760 ·Status: COMPLETED ·Phase: PHASE2

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

NCT01011283 ·Status: TERMINATED ·Phase: PHASE4

A Study of Galunisertib in Participants With Myelodysplastic Syndromes

NCT02008318 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

NCT03335943 ·Status: UNKNOWN ·Phase: PHASE4